dreyling, m. Et Al. 2017. PhD20 Updated Safety and Efficacy from the Copanlisib CHRONOS-1 Trial in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma: Low Incidence of Late-Onset Severe Toxicities. ASH .

dreyling, m., santoro, a., mollica, l., leppa, s., fallows, g., lenz, g., ... kim, w. s.(2017). PhD20 Updated Safety and Efficacy from the Copanlisib CHRONOS-1 Trial in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma: Low Incidence of Late-Onset Severe Toxicities . ASH

dreyling, martin Et Al. "PhD20 Updated Safety and Efficacy from the Copanlisib CHRONOS-1 Trial in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma: Low Incidence of Late-Onset Severe Toxicities," ASH, 2017

dreyling, martin Et Al. "PhD20 Updated Safety and Efficacy from the Copanlisib CHRONOS-1 Trial in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma: Low Incidence of Late-Onset Severe Toxicities." ASH , 2017

dreyling, m. Et Al. (2017) . "PhD20 Updated Safety and Efficacy from the Copanlisib CHRONOS-1 Trial in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma: Low Incidence of Late-Onset Severe Toxicities." ASH .

@conferencepaper{conferencepaper, author={martin dreyling Et Al. }, title={PhD20 Updated Safety and Efficacy from the Copanlisib CHRONOS-1 Trial in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma: Low Incidence of Late-Onset Severe Toxicities}, congress name={ASH}, city={}, country={}, year={2017}}